Lack of Effectiveness of Adjuvant Alternating Chemotherapy in Node-Positive, Estrogen-Receptor-Negative Premenopausal Breast Cancer Patients: Results of a Multicentric Italian Study
| Autor: | Eugenio Villa, Alessandra Rubagotti, Francesco Boccardo, Paolo Pacini, Piero Sismondi, Biagio Agostara, Antonio Farris, Luigi Gallo, Domenico Amoroso, Mario Mesiti, Alessandra Perrotta |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Cancer Research
medicine.medical_specialty Vincristine Chemotherapy Cyclophosphamide business.industry medicine.medical_treatment General Medicine Gastroenterology Nitrogen mustard Surgery chemistry.chemical_compound Oncology chemistry Fluorouracil Median follow-up Internal medicine medicine Vindesine business medicine.drug Epirubicin |
| Zdroj: | Cancer Investigation. 15:505-512 |
| ISSN: | 1532-4192 0735-7907 |
| Popis: | A multicentric randomized trial was performed in premenopausal women with node-positive, estrogen-receptor-negative breast tumors to assess the potential superiority of alternating adjuvant chemotherapy over ‘standard’ CMF chemotherapy. Between January 1989 and June 1992, 107 patients were entered into the study and randomly allocated to receive either cyclophosphamide 100 mg/m2 per os on days 1-14, methotrexate 40 mg/m2 and 5-fluorouracil 600 mg/m2 intravenously (IV) on days 1, 8 (CMF), every 4 weeks for a total of 6 cycles, or the following regimens: CMF as previously; epidoxorubicin 75 mg/m2 IV on day I and vincristine 0.75 mg/m2 IV on days 1, 8 (EV); mitomycin-C 10 mg/m2 IV on day 1 and vindesine 2 mg/m2 IV on days 1, 8 (MVs). The three regimens were given every 4 weeks for a total of 6 cycles according to the following schedule: CMF, EV, MVs, CMF, EV, MVs. At a median follow up of 48 months (range 30-72), 40 patients have relapsed and 17 have died overall. More patients in the triple-combination arm ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|